Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit
New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation
SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® NGS Library Prep kit for Plasmid Sequencing. This NGS Library Prep kit enables on-demand and automated library preparation of plasmid DNA for use in next-generation sequencing applications.
Leveraging this new automation capability of the BioXp® platform is expected to enable researchers in high-throughput discovery workflows to reduce hands-on time, cost, and steps of NGS Library Preparation, both accelerating their time to answer and reducing barriers to access to Next-Generation Sequencing.
“This kit represents a major milestone in the evolution of the BioXp® System as it now provides customers with a complete solution in many synthetic biology and genomics workflows. Throughout 2023 we plan to continue to expand capabilities for NGS Library Preparation as well as for DNA and mRNA synthesis beginning from the customer’s sequence, linear DNA, or plasmid DNA. We believe that this transformation of the BioXp platform to an automated molecular biology workstation, will empower researchers with an integrated workflow solution to streamline synthetic biology and multiomic applications throughout discovery. Thus, creating efficiencies in and accelerating their overall discovery process,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
“In our work manufacturing plasmid DNA for vaccine, gene therapy, or other R&D applications, it is critical to confirm the quality of our end product through DNA sequencing, but the commonly employed sample preparation methods are time consuming and labor intensive. We are pleased to be an Early Access partner with Telesis Bio as we believe their vision for the BioXp platform can help further accelerate and streamline our workflow,” said Santhosh Kallivalappil, Co-founder & Executive Director R&D of Novel Biotechnologies Inc.
For more information on BioXp® NGS Library Prep Kits please visit: telesisbio.com/products/bioxp-kits/ngs/
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® systems consolidate, automate, and optimize the entire synthesis, cloning and amplification workflow. As a result, they deliver virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
About Novel Biotechnology Inc.
Novel Biotechnology Inc. is on a mission to develop disruptive platforms that address unmet needs in the life sciences and pharmaceutical domains. Their focus is on developing new solutions for manufacturing plasmid DNA, a critical starting material for gene therapy, cell engineering, mRNA therapy and vaccine applications. They are developing a platform that is safe, scalable, adaptable to different plasmid backbones and payloads, has improved product quality, and is many times more productive than existing systems. Through their services business, they are currently offering plasmid DNA manufacturing services to a growing base of customers.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Vice President of Investor Relations
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bang & Olufsen A/S – finanskalender30.5.2023 16:49:43 CEST | pressemeddelelse
Herved følger offentliggørelsesdatoer for Bang & Olufsens planlagte finansielle rapporter samt datoer for generalforsamlinger i 2023 og 2024. Delårsrapporter og årsrapporter vil blive offentliggjort de anførte datoer om morgenen. 2023 Torsdag 6. juliÅrsrapport 2022/23 Torsdag 17. augustGeneralforsamling (Seneste frist for emner til dagsordenen er 6. juli) Onsdag 11. oktoberDelårsrapport (1. kvartal 2023/24) 2024 Onsdag 10. januarDelårsrapport (2. kvartal 2023/24) Onsdag 10. aprilDelårsrapport (3. kvartal 2023/24) Torsdag 4. juliÅrsrapport 2023/24 Torsdag 15. augustGeneralforsamling (Seneste frist for emner til dagsordenen er 4. juli) For yderligere information, kontakt venligst: Cristina Rønde Hefting Investor Relations Phone: +45 4153 7303 Vedhæftet fil BO_2209_Financial calendar 2023-24_DK
Bang & Olufsen A/S – financial calendar30.5.2023 16:49:43 CEST | Press release
Please be informed of the following dates for Bang & Olufsen’s planned publication of financial reports and dates for Annual General Meetings in 2023 and 2024. Interim reports and annual reports are expected to be published in the morning on the listed dates. 2023 Thursday 6 JulyAnnual report 2022/23 Thursday 17 AugustAnnual General Meeting (Deadline for subjects and proposals to the agenda is 6 July) Wednesday 11 OctoberInterim report (1st quarter 2023/24) 2024 Wednesday 10 January Interim report (2nd quarter 2023/24) Wednesday 10 AprilInterim report (3rd quarter 2023/24) Thursday 4 JulyAnnual report 2023/24 Thursday 15 AugustAnnual General Meeting (Deadline for subjects and proposals to the agenda is 4 July) For further information, please contact: Cristina Rønde Hefting Investor Relations Phone: +45 4153 7303 Attachment BO_2209_Financial calendar 2023-24_UK
Darca’s Educational Leadership Accelerator Addresses Shortage of School Principals30.5.2023 15:57:45 CEST | Press release
Innovative Training Program Aims to Address Shortage of School Leaders in Israeli Schools HOLON, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- Darca Schools, a leading school network providing equal educational opportunities for Israel’s most underserved communities, is today well underway into the second year of its innovative training program, the Education Leadership Accelerator (ELA). This groundbreaking program fully funded by the Azrieli Foundation is part of an ongoing effort to lift Israel’s entire high school education system. “The biggest drivers of positive change in our high schools are principals, and excellent leadership is a key tenet of our successful approach. It’s clear that schools in Israel are struggling to recruit and retain exceptional leaders for these under-resourced, underappreciated and overworked roles,” said Dr. Gil Pereg, founding CEO of Darca Schools. “To fill this critical vacuum of leadership that brings about positive change, the ELA program has shown it gr
Ress Life Investment A/S announces capital increase30.5.2023 15:54:15 CEST | Press release
Ress Life Investments A/S Nybrogade 12, 1203 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 30 May 2023 Corporate Announcement 19/2023 Ress Life Investments A/S announces capital increase. The Board of Directors in Ress Life Investments A/S has today resolved to utilise its authorisation in article 4.8 of the articles of association to increase the company's share capital with nominally EUR 625,000 by issuance of 1,250 new shares with a nominal value of EUR 500 each at a price of EUR 2184.16 per share of EUR 500 without pre-emption rights for the company's existing shareholders. After the capital increase, the registered share capital of the company is EUR 84,760,500 divided into 169,521 shares of EUR 500 nominal value each. Each share of nominal EUR 500 carries one vote at general meetings in Ress Life Investments A/S. The new shares will be admitted for trading and official listing on NASDAQ Copenhagen A/S under the same ISIN code as the
Mandatory Notification of Trade30.5.2023 15:43:14 CEST | Press release
Please refer to the attached forms of notification of transaction by primary insiders under the DNO ASA Employee Synthetic Share Program. This notification has been submitted pursuant to the Norwegian Securities Trading Act § 5-12 and MAR Article 19 no. 3. Attachments Form of Notification Cash Settlement Geir Arne Skau 26 05 2023Form of Notification Cash Settlement Haakon Sandborg 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Chris Spencer 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Geir Arne Skau 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Haakon Sandborg 26 05 2023Form of Notification Cash Settlement Chris Spencer 26 05 2023